Safety and efficacy of MIM-D3 ophthalmic solutions in a randomized, placebo-controlled Phase 2 clinical trial in patients with dry eye.
about
Therapeutic Strategies to Treat Dry Eye in an Aging PopulationAn evaluation of Retaine™ ophthalmic emulsion in the management of tear film stability and ocular surface staining in patients diagnosed with dry eyeCorneal sensitivity following lacrimal gland excision in the rat.Dysfunctional tear syndrome: dry eye disease and associated tear film disorders - new strategies for diagnosis and treatment.Changing trends in the treatment of dry-eye disease.An update on dry eye disease molecular treatment: advances in drug pipelines.The Future of Dry Eye Treatment: A Glance into the Therapeutic Pipeline.Investigational drugs in dry eye disease.Analysis of the Pathogenic Factors and Management of Dry Eye in Ocular Surface DisordersUse of the Controlled Adverse Environment (CAE) in Clinical Research: A Review.Neuropathic pain and dry eye.Ocular Effects of Sulfur Mustard and Therapeutic Approaches.Controlled Adverse Environment Chambers in Dry Eye Research.[Novel current and future therapy options for treatment of dry eye disease].Blink: Characteristics, Controls, and Relation to Dry Eyes.Therapeutic inhibitors for the treatment of dry eye syndrome.Current and emerging therapy of dry eye disease. Part A: pharmacological modalities
P2860
Q26822610-C53519CB-6900-4714-8613-54C3AFA93D11Q35094304-28BF22F7-DD0C-4D3F-B44A-F37350B73A97Q35678783-5F8643E2-A091-459E-93F7-EFE5914B374BQ36252489-26291175-237F-4166-B4D0-E7EEF1C8ADC4Q38148616-DF3FB144-EB1D-420F-B5BC-A2D4A392E0FFQ38207723-3E5791BF-7E2F-476A-BF79-8875EE61680FQ38569837-8DC7695F-47C9-4EBE-B1C2-6328CC582F9FQ38984001-9D6473EC-88BB-477C-AC04-56C343F5B3FCQ41574217-B255742E-B7AE-4858-9C88-CCDCD1B81AD8Q47100458-335511A4-5AFD-4FFF-A644-CB288100E15FQ47739620-F8678F50-E8AC-44CB-AB18-F65686F3D023Q47993522-6835C8BC-5790-4E9E-8D3A-1F73D701E14DQ48236970-3E0F5438-D187-49AC-834D-700DC0C88AB4Q50039889-33249793-8CFD-4678-A93D-38CBB8607BE9Q50086774-3C2B9DD3-1B72-4296-AC85-ED3825CEC0E3Q50110517-891E4E15-A12F-4D6C-8BFF-A7EF6F21C084Q57378488-5823AE81-C3ED-481F-AD1C-868ED13283E4
P2860
Safety and efficacy of MIM-D3 ophthalmic solutions in a randomized, placebo-controlled Phase 2 clinical trial in patients with dry eye.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Safety and efficacy of MIM-D3 ...... rial in patients with dry eye.
@en
type
label
Safety and efficacy of MIM-D3 ...... rial in patients with dry eye.
@en
prefLabel
Safety and efficacy of MIM-D3 ...... rial in patients with dry eye.
@en
P2093
P2860
P356
P1476
Safety and efficacy of MIM-D3 ...... rial in patients with dry eye.
@en
P2093
Gail Torkildsen
Garth Cumberlidge
George W Ousler
Heidi Goldfarb
John Lonsdale
Karen Meerovitch
Teresa Lama
P2860
P304
P356
10.2147/OPTH.S44688
P407
P577
2013-06-26T00:00:00Z